|  |  | 
    			
        			|  | Module 1: The Drug Development Process |  | 
				
				  	| 1. 2.
 3.
 4.
 5.
 | The Goal of Clinical Research Preclinical and Clinical Research
 Phases of Clinical Research
 The Process of Developing a Drug through Clinical Research
 Common Obstacles
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 2: The Role of the Principal Investigator |  | 
				
				  	| 1. 2.
 3.
 4.
 | What is a Principal Investigator (PI)? FDA Form 1572
 Principal Investigator Responsibilities
 GCP Guidelines for Investigators
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 3: Informed Consent |  | 
				
				  	| 1. 2.
 3.
 | What is Informed Consent? FDA Requirements (Sample ICF Review)
 Developing and Informed Consent Form
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 4: The Clinical Research Protocol |  | 
				
				  	| 1. 2.
 3.
 4.
 5.
 | FDA/GCP Requirements Working with the Clinical Research Protocol
 Protocol Deviations
 Protocol Compliance
 Creating Tools that Aid in Protocol Adherence
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 5: Understanding Adverse Events |  | 
				
				  	| 1. 2.
 3.
 4.
 | What is an Adverse Event What is a Serious Adverse Event
 Documenting and Reporting Adverse Events
 IND Safety Reports
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 6: Source Documentation |  | 
				
				  	| 1. 2.
 3.
 4.
 | What are Source Documents? Examples of Source Documents Used in Clinical Research
 How to Maintain Adequate Source Documentation
 What are Sponsor Companies Looking For?
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 7: Essential Documents |  | 
				
				  	| 1. 2.
 3.
 4.
 | What are Essential Documents? GCP Guidelines for Essential Documents
 Maintaining Essential Documents
 Communicating and Corresponding with the IRB
 |  | 
				
				  	|  |  | 
				
				  	|  | Module 8: Non-Compliance, Fraud and FDA Suspension |  |  | 
				
				  	| 1. 2.
 3.
 4.
 5.
 6.
 | What is Noncompliance? What is Fraud?
 Why the FDA may Disqualify an Investigator
 4FDA Disqualification Process
 An Example of an FDA Warning Letter
 Clinical Investigator Inspection List, FDA Investigator Disqualification List, List of Assurances Accepted for Future Performance of Studies with Investigational Product
 |  | 
				
				  	|  |  | 
				
				  	|  | Appendix 1: |  | 
				
				  	|  | FDA Regulations in Clinical Research Title 21 CRF – Food and Drug Administration
 | 
				
				  	| 1. 2.
 3.
 4.
 5.
 6.
 7.
 8.
 9.
 10.
 | CFR Part 11: Electronic Records; Electronic Signatures CFR Part 50: Protection of Human Subjects
 CFR Part 54: Financial Disclosure by Clinical Investigators
 CFR Part 56: Institutional Review Boards
 CFR Part 312: Investigational New Drug Application
 CFR Part 314: Application for FDA Approval to Market a New Drug
 CFR Part 320: Bioavailability and Bioequivalence Requirements
 CFR Part 601: Licensing
 CFR Part 812: Investigational Device Exemptions
 CFR Part 814: Premarket Approval of Medical Devices
 |  | 
				
				  	|  |  | 
				
				  	|  | Appendix 2: |  | 
				
				  	|  | Guidance for Industry E6 Good Clinical Practice Consolidated Guidance
 ICH 1996
 |  | 
				
				  	| 1. 2.
 3.
 4.
 5.
 6.
 7.
 8.
 9.
 | Introduction Glossary
 The Principles of ich GCP
 IRB/IEC
 Investigator
 Sponsor
 Clinical Trial Protocol
 Investigator’s Brochure
 Essential Documents
 |  | 
				
				  	|  | Appendix 3: |  | 
				
				  	|  | Sample Informed Consent Form | 
				
					|    | 
				
				  	|  | Print This Agenda: Printer Friendly |  | 
				
				  	| To enroll in this training program Click Here, or to request more information please contact us at (508) 865-8907. You may also request more information through our online form for specific service information and pricing. Other training programs are available through CRCI upon request. |  | 
				
				  	|  |  |  |  |  |